Kondru arrives at a transition point for the Rockville-based company, which has historically focused on scientific rigor for public health programs, including long-standing NIH infectious disease research and COVID-19 initiatives. The board’s decision prioritizes his background in scaling technology platforms to modernize the firm’s legacy clinical services. He aims to merge the company's established research expertise with AI-driven methodologies to reduce the time required to bring therapies to market.

His credentials include a tenure as Co-CEO of Medidata Solutions and executive roles at Janssen Americas, UCB Pharma, and F. Hoffmann-La Roche. With 25 years of experience spanning academia and global healthcare technology, Kondru is tasked with unifying the company’s specialized business units—including Emmes Government CRO and OptymEdge—under a cohesive, technology-first strategy. He holds a Ph.D. from the University of Pittsburgh and an undergraduate degree from the Indian Institute of Technology in Bombay.